Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, ...
Mayo Clinic on MSN
COVID-19 vaccines: Get the facts
The 2025-2026 COVID-19 vaccines available in the United States include Moderna, Pfizer-BioNTech and Novavax. The vaccines are all approved for people age 65 and older. Each vaccine also is approved ...
There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for ...
Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.
Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...
Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...
Novavax raised its full-year 2025 revenue framework, now expecting adjusted total revenue between $1.04 billion and $1.06 ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s the second time the firm ...
CHICAGO, Oct 30 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Friday outlined specific diversity targets for its large-scale COVID-19 vaccine study expected to begin in the United States and ...
Discover Novavax's Q3 2025 earnings: partnership-driven strategy, cost savings, increased revenue outlook, and pipeline progress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback